Implications of point-of-care testing for hemoglobin A1c

Diabetes Technology and Therapeutics

Volumn 2, Issue 4, 2000, Pages 527-528

  Porter, K H ^a   Myers, G L ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERTIFICATION; COST; DIABETES CONTROL; DIAGNOSTIC PROCEDURE; HEMOGLOBIN DETERMINATION; HOME MONITORING; HUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; SELF MONITORING; SHORT SURVEY;

BLOOD GLUCOSE; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MONITORING, PHYSIOLOGIC; OFFICE VISITS; POINT-OF-CARE SYSTEMS;

EID: 0034469296     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/15209150050501925     Document Type: Short Survey

References (7)

1. A miniaturized self-contained single-use disposable quantitative test for hemoglobin A1c in blood at the point of care
2. Tests of glycemia in diabetes
3. Standards of medical care for patients with diabetes mellitus
4. The relationship of glycemic exposure (Hb A1c) to the risk of development and progression of reinopathy in the Diabetes Control and Complications Trial
5. Screening for type 2 diabetes
6. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus